Institute of Social and Preventive Medicine, University of Bern.
Institute of Global Health, University of Geneva, Switzerland.
Clin Infect Dis. 2018 Nov 13;67(11):1643-1652. doi: 10.1093/cid/ciy347.
Low retention on combination antiretroviral therapy (cART) has emerged as a threat to the Joint United Nations Programme on human immunodeficiency virus (HIV)/AIDS (UNAIDS) 90-90-90 targets. We examined outcomes of patients who started cART but were subsequently lost to follow-up (LTFU) in African treatment programs.
This was a systematic review and individual patient data meta-analysis of studies that traced patients who were LTFU. Outcomes were analyzed using cumulative incidence functions and proportional hazards models for the competing risks of (i) death, (ii) alive but stopped cART, (iii) silent transfer to other clinics, and (iv) retention on cART.
Nine studies contributed data on 7377 patients who started cART and were subsequently LTFU in sub-Saharan Africa. The median CD4 count at the start of cART was 129 cells/μL. At 4 years after the last clinic visit, 21.8% (95% confidence interval [CI], 20.8%-22.7%) were known to have died, 22.6% (95% CI, 21.6%-23.6%) were alive but had stopped cART, 14.8% (95% CI, 14.0%-15.6%) had transferred to another clinic, 9.2% (95% CI, 8.5%-9.8%) were retained on cART, and 31.6% (95% CI, 30.6%-32.7%) could not been found. Mortality was associated with male sex, more advanced disease, and shorter cART duration; stopping cART with less advanced disease andlonger cART duration; and silent transfer with female sex and less advanced disease.
Mortality in patients LTFU must be considered for unbiased assessments of program outcomes and UNAIDS targets in sub-Saharan Africa. Immediate start of cART and early tracing of patients LTFU should be priorities.
联合抗逆转录病毒疗法(cART)的保留率低,已成为联合联合国艾滋病毒/艾滋病规划署(UNAIDS)90-90-90 目标的威胁。我们研究了在非洲治疗项目中开始接受 cART 但随后失访(LTFU)的患者的结局。
这是一项系统评价和个体患者数据荟萃分析,对追踪失访患者的研究进行了分析。使用累积发病率函数和比例风险模型分析了死亡、存活但停止 cART、沉默转移到其他诊所和保留 cART 的竞争风险的结果。
9 项研究提供了数据,涉及撒哈拉以南非洲地区开始接受 cART 后随后失访的 7377 名患者。cART 开始时的中位 CD4 计数为 129 个细胞/μL。最后一次就诊后 4 年,已知有 21.8%(95%置信区间[CI],20.8%-22.7%)死亡,22.6%(95% CI,21.6%-23.6%)存活但停止了 cART,14.8%(95% CI,14.0%-15.6%)转移到另一家诊所,9.2%(95% CI,8.5%-9.8%)保留了 cART,31.6%(95% CI,30.6%-32.7%)无法找到。死亡率与男性、更晚期疾病和更短的 cART 持续时间有关;停止 cART 与疾病较轻和 cART 持续时间较长有关;而沉默转移与女性和较轻的疾病有关。
在评估撒哈拉以南非洲的项目结果和 UNAIDS 目标时,必须考虑失访患者的死亡率。应优先考虑立即开始 cART 并尽早追踪失访患者。